Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed diagnosis of one the following:
• * Acute myelogenous leukemia in CR1, ER1, CR2, ER2, CR3
• * Acute lymphocytic leukemia in CR1, ER1, CR2, ER2, CR3
• * Non-Hodgkin's lymphoma
• * Hodgkin's lymphoma
• * Multiple myeloma with no more than 12 months of prior alkylator based chemotherapy
• * Myelodysplastic syndrome (MDS)
• * Acute leukemia arising out of MDS
• * Primary resistant acute leukemia
• * Chronic myelomonocytic leukemia
• * Aplastic anemia (40 years of age and over)
• * Solid tumor malignancy (germ cell, sarcoma, breast, etc.)
• * Genetic disorders or inborn errors of metabolism as defined by preparative regimen protocol
• * Chronic myelogenous leukemia
• No aplastic anemia under 40 years of age or myelofibrosis
• PATIENT CHARACTERISTICS:
• Age:
• 0.5 to 65
• Performance status:
• Not specified
• Life expectancy:
• Not specified
• Hematopoietic:
• Not specified
• Hepatic:
• Not specified
• Renal:
• Not specified
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior red blood cell or platelet transfusions from a sibling donor
• Chemotherapy:
• Not specified
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Not specified